1 / 8

Analyze future: Status Epilepticus -Pipeline Review, H2 2014

Global Markets Direct’s, ‘Status Epilepticus - Pipeline Review, H2 2014’, provides an overview of the Status Epilepticus’s therapeutic pipeline. To Get More Info. Visit: http://www.analyzefuture.com/status-epilepticus-pipeline-review-h2-2014-market This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Status Epilepticus and special features on late-stage and discontinued projects.

mcalpin_ronald
Download Presentation

Analyze future: Status Epilepticus -Pipeline Review, H2 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Status Epilepticus - Pipeline Review, H2 2014 No. Pages : 41 Published on : Dec-2014

  2. Report Description Global Markets Direct’s, ‘Status Epilepticus - Pipeline Review, H2 2014’, provides an overview of the Status Epilepticus’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Status Epilepticus and special features on late-stage and discontinued projects. To Get More Info. Visit : http://www.analyzefuture.com/status-epilepticus-pipeline-review-h2-2014-market Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

  3. Report Description Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. To Enquire About Report @ http://www.analyzefuture.com/status-epilepticus-pipeline-review-h2-2014-market/report-enquiry The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

  4. Table of Content Table Of ContentsTable of ContentsTable of Contents 2List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Status Epilepticus Overview 6Therapeutics Development 7Pipeline Products for Status Epilepticus - Overview 7Pipeline Products for Status Epilepticus - Comparative Analysis 8Status Epilepticus - Therapeutics under Development by Companies 9Status Epilepticus - Therapeutics under Investigation by Universities/Institutes 10Status Epilepticus - Pipeline Products Glance 11Clinical Stage Products 11Early Stage Products 12Unknown Stage Products 13Status Epilepticus - Products under Development by Companies 14

  5. Table of Content Status Epilepticus - Products under Investigation by Universities/Institutes 15Status Epilepticus - Companies Involved in Therapeutics Development 16Ligand Pharmaceuticals, Inc. 16Sage Therapeutics 17Status Epilepticus - Therapeutics Assessment 18Assessment by Monotherapy Products 18Assessment by Target 19Assessment by Mechanism of Action 21Assessment by Route of Administration 23Assessment by Molecule Type 25Drug Profiles 26ADD-405008 - Drug Profile 26Product Description 26Mechanism of Action 26R&D Progress 26fosphenytoin sodium - Drug Profile 27Product Description 27Mechanism of Action 27R&D Progress 27SAGE-217 - Drug Profile 28

  6. Table of Content Product Description 28Mechanism of Action 28R&D Progress 28SAGE-547 - Drug Profile 29Product Description 29Mechanism of Action 29R&D Progress 29SAGE-689 - Drug Profile 31Product Description 31Mechanism of Action 31R&D Progress 31SGE-102 - Drug Profile 32Product Description 32Mechanism of Action 32R&D Progress 32Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 33Product Description 33Mechanism of Action 33R&D Progress 33

  7. Table of Content TG-4155 - Drug Profile 34Product Description 34Mechanism of Action 34R&D Progress 34Status Epilepticus - Recent Pipeline Updates 35Status Epilepticus - Dormant Projects 38Status Epilepticus - Product Development Milestones 39Featured News & Press Releases 39Apr 04, 2013: Sage Therapeutics Presents Clinical Data On SGE-102 At 4th London-Innsbruck Colloquium On Status Epilepticus And Acute Seizures Conference 39Appendix 40Methodology 40Coverage 40Secondary Research 40Primary Research 40Expert Panel Validation 40 To Get Complete TOC Visit at: http://www.analyzefuture.com/status-epilepticus-pipeline-review-h2-2014-market/table-of-contents

  8. FOR MORE DETAILS Visit us at : http://www.analyzefuture.com/ Stay With Us: 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States. TELEPHONE: +1 (855) 711-1555 EMAIL: sales@analyzefuture.com

More Related